ABSTRACT
Objective To evaluate the short-term efficacy,safety and impact on the quality of life of anlotinib in third-line and above treatment for advanced non-small cell lung cancer (NSCLC) patients.Methods All the patients received alotinib 12 mg/d.One cycle was defined as 2 weeks on-treatment followed by 1 week off-treatment until disease progression or treatment intolerance.Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to assess tumor responses.Common Terminology Criteria for Adverse Events (CTCAE) 4.02 was used to assess the adverse events.The European Organization for Research on Treatment of Cancer (EORTC) QLQ-C30 and QLQ-LC13 were used to assess quality of life.Results Among 27 patients in study,no complete response (CR) was found,2 patients (7.4％) achieved partial response (PR),16 patients (59.3％) achieved stable disease (SD),9 patients (33.3％) achieved progressive disease (PD),objective response rate (ORR) was 7.4％,and disease control rate (DCR) was 66.7％.The scores of physical functioning (76.00 ± 10.55 vs.64.44 ± 11.59),emotional functioning (81.67 ± 8.71 vs.76.11 ±6.71) and global health status (48.87 ±7.97 vs.40.56 ± 12.49) of the QLQ-C30 scale after treatment were higher than those before treatment,with statistically significant differences (t =-4.516,P ＜0.001;t=-2.646,P=0.019;t=-3.872,P=0.002).Fatigue (50.37±8.95 vs.40.74±13.86),nausea and vomiting (26.54 ± 16.18 vs.14.20 ± 11.97),loss of appetite [M(QR):33.33 (33.33) vs.33(33.33)] were better than before (t =-2.476,P =0.027;t =-5.036,P ＜0.001;Z =-2.923,P =0.003);pain (28.88 ± 14.23 vs.33.33 ± 13.60) and dyspnea [33.33 (33.33) vs.33.33 (66.67)] scores were lower than before (t =3.674,P =0.003;Z =-3.266,P =0.001).The scores of cough (24.44 ±19.12 vs.45.24 ±20.34),shortness of breath [11.11(22.22) vs.33.33(22.22)] and chest pain [0.00(33.33)vs.33.33 (33.33)] in the QLQ-LC13 scale after treatment were lower than those before treatment,with statistically significant differences (t =4.000,P =0.001;Z =-4.125,P ＜0.001;Z =-1.890,P =0.034);the scores of sore mouth or tongue [0.00(33.33) vs.0.00(0.00)] and hands and feet tingling [33.33(33.33) vs.0.00(0.00)] were higher than before (Z=-2.000,P=0.046;Z=-2.264,P=0.024).Common adverse reactions included hypertension,fatigue,elevated thyroid stimulating hormone,proteinuria,hand-foot syndrome,oral mucositis,hemoptysis,etc,mainly grade 1-2,and they were all improved after the treatments.Conclusion Anlotinib as a third-line and further therapy is positive effected and well tolerated.It can alleviate the clinical symptoms and significantly improve the quality of life of NSCLC patients.
ABSTRACT
Objective To investigate the clinical application effects of gabapentin in the treatment of recurrent trigeminal neuralgia.Methods 68 patients with recurrent trigeminal neuralgia were chosen as study subjects,and they were divided into control group and research group according to the digital table.The research group was treated with gabapentin,the control group was treated with carbamazepine.After treatment for 4 weeks,the clinical effects,life satisfactory index,pain,drug dosage and adverse reaction between the two group were compared.Results Each group had 32 patients completed the study.The total effective rate of the research group was higher than that of the control group(68.75％ vs.59.37％),the difference was not statistically significant(x2 =0.611,P ＜0.05).The average gabapentin dosage in the research group was higher than the average carbamazepine dosage in the control group,the difference was statistically significant (t =11.278,P ＜ 0.05).Before treatment,the VAS scores between the two groups had no statistically significant difference (t =0.153,P ＞ 0.05).At 7 d after treatment,the VAS scores in the research group was lower than that in the control group [(4.09 ± 0.83) points vs.(4.63 ± 0.79) points],the difference was statistically significant (t =2.666,P ＜ 0.05).At 14 d and 28 d after treatment,the VAS scores between the two groups had no statistically significant difference (t =1.527,0.352,all P ＞ 0.05).Before treatment and 7 d after treatment,the life satisfaction index B (LSI-B) scores between the two groups had no statistically significant difference(t =0.049,0.224,all P ＞ 0.05).At 14 d and 28 d after treatment,LSI-B scores in the two groups were both increased,which in the research group was higher than taht in the control group[14 d:(15.09 ± 3.68) points vs.(12.91 ± 3.45) points,28 d:(16.48 ± 3.43) points vs.(13.35 ± 3.14) points],the differences were statistically different(t =2.445,3.808,all P ＜ 0.05).The incidence rate of adverse reaction of the research group was lower than that of the control group(15.63％ vs.37.50％),the difference was statistically significant (x2 =3.925,P ＜ 0.05).Conclusion Gabapentin has similar treatment effects in recurrent trigeminal neuralgia as carbamazepin,and gabapentin has better improvement in patients'life quality,and with better safety.